Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Trends Biochem Sci. 2014 Jan 2;39(2):91–100. doi: 10.1016/j.tibs.2013.12.004

Figure 2.

Figure 2

KRAS mutations in PDAC. (a) Missense mutations result in single amino acid substitutions primarily at G12 (98%), and at lower frequencies at G13 (21%) or Q61 (28%). (b) At G12, eight different amino acid substitutions have been identified, with G12D the predominant mutation (51%). (c) At G13, four different mutations have been described, with the majority G13D. (d) Mutation at Q61 also results in constitutive activation, and among the three mutations described, Q61H occurs most frequently. There is increasing evidence that the different activating mutations may not have the same biochemical and biological consequences. Data were compiled from COSMIC (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/).